Psilocybin Trials for PTSD
A single 25 mg dose of psilocybin reduced PTSD symptoms in an open-label study, highlighting psychedelics’ potential for treatment-resistant cases.
Psychedelic therapy with psilocybin is gaining traction for post-traumatic stress disorder (PTSD), with Compass Pathways’ COMP360 receiving FDA clearance for clinical trials (1). A phase 2 open-label study of a 25 mg dose demonstrated safety and preliminary efficacy, reducing symptoms in PTSD patients (2). Gary W. Small noted that PTSD affects 13 million Americans, with no specific pharmacologic options, making this a critical advancement (3). The treatment enhances neuroplasticity, aiding trauma processing, and shows promise for comorbid conditions like depression (4). While experts acknowledge potential, they emphasise the need for controlled settings and further research to address risks (5). This aligns with broader psychedelic approvals for mental health, offering supportive care for those unresponsive to standard therapies.
Footer Sources:
-
https://www.psychiatrictimes.com/view/investigational-psilocybin-for-ptsd-and-ongoing-trials – Accessed 6 February 2026.
-
https://www.youtube.com/watch?v=NJEdCg5OTKI – Accessed 6 February 2026.
-
https://www.abc.net.au/news/2025-03-04/veterans-with-ptsd-depression-may-soon-get-psychedelic-therapy/104825752 – Accessed 6 February 2026.
-
https://academic.oup.com/bmb/article/156/1/ldaf015/8266412 – Accessed 6 February 2026.
-
https://hai.stanford.edu/news/new-center-to-drive-ai-innovation-in-ptsd-treatment – Accessed 6 February 2026.